Generally, melanoma is highly responsive to various immunotherapies and nearly 40% of metastatic melanoma patients were reported as staying progression-free for over four years after treatment with a combination of ipilimumab (anti-CTLA4) and nivolumab (anti-PD-L1) [49]. The gene discussed is CD274; the disease is metastatic melanoma.